MX2011007947A - Relacionados con el hierro. - Google Patents

Relacionados con el hierro.

Info

Publication number
MX2011007947A
MX2011007947A MX2011007947A MX2011007947A MX2011007947A MX 2011007947 A MX2011007947 A MX 2011007947A MX 2011007947 A MX2011007947 A MX 2011007947A MX 2011007947 A MX2011007947 A MX 2011007947A MX 2011007947 A MX2011007947 A MX 2011007947A
Authority
MX
Mexico
Prior art keywords
iron
deferiprone
treatment
eye
prevention
Prior art date
Application number
MX2011007947A
Other languages
English (en)
Spanish (es)
Inventor
Michael Spino
Joshua Lawrence Dunaief
Original Assignee
Joshua Lawrence Dunaief
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joshua Lawrence Dunaief filed Critical Joshua Lawrence Dunaief
Publication of MX2011007947A publication Critical patent/MX2011007947A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2011007947A 2009-01-26 2009-11-12 Relacionados con el hierro. MX2011007947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14724509P 2009-01-26 2009-01-26
PCT/CA2009/001639 WO2010083582A1 (en) 2009-01-26 2009-11-12 Use of deferiprone for treatment and prevention of iron-related eye disorders

Publications (1)

Publication Number Publication Date
MX2011007947A true MX2011007947A (es) 2011-12-14

Family

ID=42355449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007947A MX2011007947A (es) 2009-01-26 2009-11-12 Relacionados con el hierro.

Country Status (24)

Country Link
US (1) US20130023569A1 (enExample)
EP (1) EP2389179A4 (enExample)
JP (1) JP5604631B2 (enExample)
KR (1) KR20120078667A (enExample)
CN (1) CN102348456A (enExample)
AP (1) AP2011005843A0 (enExample)
AU (1) AU2009338093B2 (enExample)
BR (1) BRPI0920492A2 (enExample)
CA (1) CA2750599A1 (enExample)
CL (1) CL2011001812A1 (enExample)
CR (1) CR20110456A (enExample)
EA (1) EA201170970A1 (enExample)
IL (1) IL214291A (enExample)
MA (1) MA33090B1 (enExample)
MX (1) MX2011007947A (enExample)
MY (1) MY161269A (enExample)
NI (1) NI201100148A (enExample)
NZ (1) NZ594728A (enExample)
PE (1) PE20120515A1 (enExample)
SG (1) SG173145A1 (enExample)
TN (1) TN2011000366A1 (enExample)
UA (1) UA103366C2 (enExample)
WO (1) WO2010083582A1 (enExample)
ZA (1) ZA201105514B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016205030B2 (en) * 2015-01-09 2021-04-01 The Board Of Trustees Of The University Of Illinois Restoring physiology in iron-deficient organisms using small molecules
CN111918646B (zh) 2017-10-25 2022-02-22 奇斯药制品公司 延迟释放去铁酮片剂及其使用方法
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
WO2004041151A2 (en) * 2002-11-07 2004-05-21 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
EP1601367A2 (en) * 2003-02-06 2005-12-07 Bioresponse L.L.C. The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
DK1991225T3 (da) * 2006-02-22 2013-12-16 Apotex Technologies Inc Anvendelse af deferipron og fremgangsmåder til at behandle og/eller forebygge Friedreichs ataksi, der resulterer af intracellulær fejlhåndtering af jern
JP5290147B2 (ja) 2006-04-14 2013-09-18 プラナ バイオテクノロジー リミティッド 加齢黄斑変性症(amd)の処置方法
ITMI20061770A1 (it) * 2006-09-18 2008-03-19 Carlo Ghisalberti Metodo cosmetico di riduzione delle occhiaie
US8501789B2 (en) * 2007-01-19 2013-08-06 The Trustees Of The University Of Pennsylvania Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease

Also Published As

Publication number Publication date
EA201170970A1 (ru) 2012-03-30
MA33090B1 (fr) 2012-03-01
NI201100148A (es) 2012-03-06
BRPI0920492A2 (pt) 2019-07-09
UA103366C2 (ru) 2013-10-10
AU2009338093A1 (en) 2011-09-08
JP5604631B2 (ja) 2014-10-08
EP2389179A1 (en) 2011-11-30
AU2009338093B2 (en) 2014-08-28
JP2012515725A (ja) 2012-07-12
MY161269A (en) 2017-04-14
TN2011000366A1 (en) 2013-03-27
EP2389179A4 (en) 2012-08-29
SG173145A1 (en) 2011-08-29
NZ594728A (en) 2013-03-28
AP2011005843A0 (en) 2011-08-31
CR20110456A (es) 2012-05-31
PE20120515A1 (es) 2012-05-20
WO2010083582A1 (en) 2010-07-29
IL214291A (en) 2015-03-31
CA2750599A1 (en) 2010-07-29
US20130023569A1 (en) 2013-01-24
IL214291A0 (en) 2011-09-27
CL2011001812A1 (es) 2012-02-03
CN102348456A (zh) 2012-02-08
KR20120078667A (ko) 2012-07-10
ZA201105514B (en) 2012-10-31

Similar Documents

Publication Publication Date Title
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
WO2012050831A3 (en) Combination treatment for dermatological conditions
BR112015012312A2 (pt) método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
WO2009089494A3 (en) Pharmaceutical compositions
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2011085162A3 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
WO2013180834A3 (en) Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
NZ600874A (en) Fluorinated derivatives of deferiprone
WO2010132882A3 (en) Sublingual dexmedetomidine compositions and methods of use thereof
NZ586302A (en) Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
MX2015003035A (es) Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2012009600A (es) Metodo para estabilizar daño de articulacion en sujetos utilizando inhibidores de xantina oxidoreductasa.
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders
WO2010030976A3 (en) Methods and compositions for inhibiting atherosclerosis and vascular inflammation
CA2866819C (en) Method for treating inflammation
WO2015061777A3 (en) Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema
UA106131C2 (uk) Засіб для профілактики і лікування захворювань, які супроводжуються болем в органах сечовипускання
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
MX2010011193A (es) Composicion farmaceutica liquida para el tratamiento y prevencion del dolor.
WO2009088849A3 (en) Treatment or prevention of inflammation by targeting cyclin d1
PH12015501538A1 (en) Topical ocular analgesic agents
HK1224220A1 (zh) 治疗神经退化性失调的方法

Legal Events

Date Code Title Description
FA Abandonment or withdrawal